BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Amilpar Consolidated Revenues Increase by 61% and EBITDA Doubled in the Second Quarter 2010


8/11/2010 8:24:31 AM

RIO DE JANEIRO, Aug. 10 /PRNewswire-FirstCall/ -- Amilpar (Bovespa: AMIL3; Bloomberg: AMIL3 BZ and APAR < GO >; Reuters: AMIL3.SA), the largest healthcare company in Brazil, announced today its results for the second quarter of 2010 (2Q10).

Amil's results (without Medial)

  • Adjusted Operating Revenues totaled R$ 1,369.8 million in the second quarter of 2010, 15.1% up on the same period of last year.
  • Adjusted EBITDA came to R$ 105.7 million with a margin of 7.7% in 2Q10, representing an improvement of 1.7 p.p. over 2Q09 and accumulated R$ 243.9 million with a margin of 9.2% in the first six months.
  • The Company posted adjusted Net Income of R$ 38.1 million in the second quarter.

Medial's Results

  • Adjusted Operating Revenues totaled R$ 567.3 million in the second quarter of 2010, 4.7% up on the year before, and R$ 1,138.2 million in the first six months, 6.9% more than in 1H09.
  • Adjusted EBITDA stood at R$ 33.8 million with a margin of 5.9% in 2Q10, 7.1 p.p. higher than the adjusted margin of -1.2% recorded in the same period of last year.
  • Adjusted Net Income came to R$ 11.3 million in the second quarter, versus a loss of R$ -13.5 million in 2Q09.

Amilpar's Results (consolidated with Medial)

  • Adjusted Operating Revenues amounted to R$ 1,917.3 million in 2Q10, year-on-year growth of 61.1% and accumulated R$ 3,774.2 million in 1H10, 62.6% more than the first six months of the previous year.
  • Consolidated adjusted EBITDA totaled R$ 139.8 million in 2Q10 with a margin of 7.3%, 98.9% up on the R$ 70.3 million recorded in 2Q09.
  • Adjusted Net Income amounted R$ 49.6 million in the second quarter, 24.6 % up on 2Q09.

To access the Earnings Release full version visit our website at www.amilpar.com.br/ir

Next Events: Conference Calls

English

August 11, 2010

10 AM (New York)

(11 AM Brasilia)

Phone: +1 (412) 858-4600

Code: Amil

Webcast: www.amilpar.com.br/ir



Portuguese

August 11, 2010

1 PM (New York)

(2 PM Brasilia)

Phone: +55 (11) 2188-0155

Code: Amil

Webcast: www.amilpar.com.br/ri



IR Contact

Erwin Kleuser

Investor Relations Officer

Phone: +55 (21) 3805-1155

invest@amil.com.br

www.amilpar.com.br/ir



About Amilpar

Amil Participacoes S.A. is the largest managed care organization in Brazil, according to the ANS, currently assisting over 5 million members in the states of Sao Paulo, Rio de Janeiro, Parana, Minas Gerais, Pernambuco, Bahia and in Distrito Federal.

SOURCE Amilpar



Read at BioSpace.com

Amilpar
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES